Mayo Clinics data has women on tirzepatide plus hormone therapy losing 19.2% of body weight against 14% on tirzepatide alone
Vertical integration and capacity expansion-catalyzed by the $16.5B Catalent acquisition-create scale, quality control and distribution reliability that raise the bar for new entrants
If you always struggle with Friday injections during summer travel season, maybe Tuesday is a better permanent choice year-round
GLP-1 Medications and Their Role In Menopause Weight Gain By Cathleen Pelletreau, MSN, APRN, FNP-BC, 08/20/2024 Perimenopause and menopause often bring an array of troublesome symptoms to the daily lives of women
Why NexLife Ranks #1 in GLP-1 Editorial's 2026 Review NexLife ranks #1 because it combines low published pricing, flat dose-independent pricing, provider-supervised care, pharmacy coordination, included support services, and stronger transparency signals than most reviewed competitors
Objective data helps determine whether therapy is working and how adjustments should occur
